NO20064615L - Substituerte heteroaryl- og fenylsulfamoylforbindelser - Google Patents
Substituerte heteroaryl- og fenylsulfamoylforbindelserInfo
- Publication number
- NO20064615L NO20064615L NO20064615A NO20064615A NO20064615L NO 20064615 L NO20064615 L NO 20064615L NO 20064615 A NO20064615 A NO 20064615A NO 20064615 A NO20064615 A NO 20064615A NO 20064615 L NO20064615 L NO 20064615L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- substituted heteroaryl
- cholesterol
- levels
- triglycerides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
- C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/68—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Foreliggende oppfinnelse angår substituerte heteroaryl- og fenylsulfamoylforbindelser, farmasøytiske sammensetninger som inneholder slike forbindelser og anvendelse av slike sammensetninger som peroksisomproliferator aktivatorreseptor (PPAR) agonister. PPARa-aktivatorer, farmasøytiske sammensetninger som inneholder slike forbindelser og anvendelse av slike forbindelser for å heve visse plasmalipidnivåer, som inkluderer høytetthets lipoprotein-kolesterol og redusere visse andre plasmalipidnivåer, slik som LDL-kolesterol og triglyserider og følgelig behandle sykdommer som forsterkes ved lave nivåer av HDL-kolesterol og/eller høye nivåer av LDL-kolsterol og triglyserider, slik som aterosklerose og kardiovaskulære sykdommer, hos pattedyr, som inkluderer mennesker. Forbindelsene er også anvendelige for behandling av negativ energibalanse (NEB) og assosierte sykdommer hos drøvtyggere.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55211404P | 2004-03-10 | 2004-03-10 | |
US11/012,139 US7262318B2 (en) | 2004-03-10 | 2004-12-16 | Substituted heteroaryl- and phenylsulfamoyl compounds |
PCT/IB2005/000526 WO2005092845A1 (en) | 2004-03-10 | 2005-02-28 | Substituted heteroaryl- and phenylsulfamoyl compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20064615L true NO20064615L (no) | 2006-12-07 |
Family
ID=34960729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20064615A NO20064615L (no) | 2004-03-10 | 2006-10-10 | Substituerte heteroaryl- og fenylsulfamoylforbindelser |
Country Status (22)
Country | Link |
---|---|
US (2) | US7262318B2 (no) |
EP (1) | EP1725524A1 (no) |
JP (1) | JP2007528387A (no) |
KR (1) | KR20070001173A (no) |
AP (1) | AP2006003714A0 (no) |
AR (1) | AR048260A1 (no) |
AU (1) | AU2005225628B2 (no) |
BR (1) | BRPI0508555A (no) |
CA (1) | CA2559035A1 (no) |
DO (2) | DOP2005000025A (no) |
EA (1) | EA200601442A1 (no) |
EC (1) | ECSP066834A (no) |
IL (1) | IL177631A0 (no) |
MA (1) | MA28461B1 (no) |
NL (1) | NL1028519C2 (no) |
NO (1) | NO20064615L (no) |
PA (1) | PA8625701A1 (no) |
PE (1) | PE20051147A1 (no) |
SV (1) | SV2005002047A (no) |
TW (1) | TW200610525A (no) |
UY (1) | UY28794A1 (no) |
WO (1) | WO2005092845A1 (no) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
EP1765320A2 (en) * | 2004-05-25 | 2007-03-28 | Pfizer Products Incorporated | Use of ppar agonists to treat ruminants |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
WO2007030567A2 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | Pparactive compounds |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
US7790770B2 (en) | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
US7652023B2 (en) | 2005-11-23 | 2010-01-26 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
GB0526252D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
WO2007091140A1 (en) * | 2006-02-06 | 2007-08-16 | Pfizer Products Inc. | Substituted phenylsulfamoyl compounds as ppar agonists |
EP2070908A4 (en) * | 2006-09-07 | 2011-08-10 | Univ Okayama Nat Univ Corp | COMPOUND HAVING A BENZAMIDE SKELETER AND A SELECTIVE CYCLOOXYGENASE INHIBITORY ACTIVITY (COX-1) |
US10716798B2 (en) * | 2007-02-21 | 2020-07-21 | The Regents Of The University Of Michigan | Compositions and methods for tranquilizing heart muscle |
WO2009017863A2 (en) * | 2007-05-08 | 2009-02-05 | Burnham Institute For Medical Research | Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification |
WO2011031304A2 (en) * | 2009-09-11 | 2011-03-17 | Nestec S.A. | Compositions and methods for enhancing cognitive and related functions in animals |
KR101194995B1 (ko) * | 2009-10-14 | 2012-10-29 | 주식회사 이큐스앤자루 | 신규한 2-페닐-벤즈이미다졸 또는 2-페닐-벤즈옥사졸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 항바이러스용 약학적 조성물 |
US8546412B2 (en) * | 2011-12-21 | 2013-10-01 | Abbott Cardiovascular Systems, Inc. | Methods of treating heart failure |
CN107001267A (zh) * | 2014-08-08 | 2017-08-01 | 马合伙人株式会社 | 稠合杂环化合物 |
CN112961149A (zh) | 2014-08-11 | 2021-06-15 | 安吉恩生物医药公司 | 细胞色素p450抑制剂及其用途 |
CA2970819A1 (en) | 2014-12-31 | 2016-07-07 | Angion Biomedica Corp. | Methods and agents for treating disease |
US20220220069A1 (en) * | 2017-08-10 | 2022-07-14 | Shanghai Jiaotong University School Of Medicine | Compound used as sirt6 small-molecule allosteric activator and pharmaceutical composition thereof |
AU2019207491A1 (en) * | 2018-01-10 | 2020-07-30 | Cura Therapeutics, Llc | Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications |
US20230233531A1 (en) * | 2022-01-25 | 2023-07-27 | University Of Houston System | Use of non-steroidal anti-inflammatory compounds for treatment of inflammation |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB378179A (en) | 1930-08-04 | 1932-08-11 | American Safety Navigation Com | Improvement in boat-launching devices |
CH507249A (de) * | 1968-05-31 | 1971-05-15 | Sandoz Ag | Verfahren zur Herstellung von 2-Brom-a-ergokryptin |
US3658990A (en) | 1969-06-10 | 1972-04-25 | Ciba Geigy Corp | Diuretic compositions |
US3806542A (en) | 1969-06-10 | 1974-04-23 | Ciba Geigy Corp | 5-arylsulfamyl-anthranilic acids |
US3843662A (en) | 1971-12-09 | 1974-10-22 | Pfizer | 2-halo-5-(substituted piperidino sulfonyl)benzoic acids |
US3812104A (en) | 1971-06-25 | 1974-05-21 | Ciba Geigy Corp | 5-arylsulfamyl-anthranilic acids |
CH558789A (de) | 1971-08-19 | 1975-02-14 | Ciba Geigy Ag | Verfahren zur herstellung der neuen 5-(2-aminophenylsulfamoyl)-4-chlor-n-furfryl-anthranilsaeure und ihrer salze. |
US3992441A (en) * | 1972-12-26 | 1976-11-16 | Pfizer Inc. | Sulfamylbenzoic acids |
US4377521A (en) * | 1972-12-26 | 1983-03-22 | Pfizer Inc. | Sulfamylbenzoic acids |
US4062950A (en) * | 1973-09-22 | 1977-12-13 | Bayer Aktiengesellschaft | Amino sugar derivatives |
US3879402A (en) | 1973-09-26 | 1975-04-22 | Pfizer | Process for preparing 2-chloro-5-sulfamoylbenzoic acids |
US3894033A (en) * | 1974-05-16 | 1975-07-08 | Pfizer | 5-Aryltetrazoles |
US3929803A (en) | 1974-05-28 | 1975-12-30 | Pfizer | Aryl carboxylic acids |
JPS5612114B2 (no) * | 1974-06-07 | 1981-03-18 | ||
NO154918C (no) * | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
JPS5953920B2 (ja) * | 1977-12-28 | 1984-12-27 | 東洋醸造株式会社 | 新規なアミノ糖化合物およびその製法 |
CA1121290A (en) * | 1978-02-14 | 1982-04-06 | Yasuji Suhara | Amino sugar derivatives |
US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4450171A (en) * | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
ES8207217A1 (es) * | 1980-10-09 | 1982-09-01 | Hoechst Ag | Procedimiento para la preparacion de un inactivador de alfa-amilasa |
WO1983000013A1 (en) | 1980-11-10 | 1983-01-06 | Mochida Pharm Co Ltd | Medicinal composition having an antiviral effect |
JPS5817167B2 (ja) | 1980-11-10 | 1983-04-05 | 持田製薬株式会社 | 抗ウイルス作用を有する医薬組成物 |
EP0056194B1 (en) * | 1981-01-05 | 1984-09-12 | Takeda Chemical Industries, Ltd. | N-substituted pseudo-aminosugars, their production and use |
EP0068407A1 (en) | 1981-06-22 | 1983-01-05 | Hodogaya Chemical Co., Ltd. | Aminosulfonylbenzoic acid derivatives |
US4495439A (en) | 1981-09-02 | 1985-01-22 | Tokyo Shibaura Denki Kabushiki Kaisha | Magnetic focusing type cathode ray tube |
DK161312C (da) * | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
US4448784A (en) * | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
FI844289L (fi) * | 1984-01-21 | 1985-07-22 | Hoechst Ag | Nya polypeptider med -amylashaemmande verkan, foerfarande foer deras framstaellning, deras anvaendning och farmaceutiska preparat. |
US4634765A (en) * | 1984-12-18 | 1987-01-06 | Merrell Dow Pharmaceuticals Inc. | Homodisaccharide hypoglycemic agents |
US5061798A (en) * | 1985-01-18 | 1991-10-29 | Smith Kline & French Laboratories, Ltd. | Benzyl pyridyl and pyridazinyl compounds |
GB8501372D0 (en) * | 1985-01-18 | 1985-02-20 | Smith Kline French Lab | Chemical compounds |
GB8531071D0 (en) * | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
GB8608335D0 (en) * | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
US5041432A (en) * | 1987-01-30 | 1991-08-20 | E. I. Du Pont De Nemours And Company | Steroid derivatives useful as hypocholesterolemics |
JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US5192772A (en) * | 1987-12-09 | 1993-03-09 | Nippon Shinyaku Co. Ltd. | Therapeutic agents |
US4804770A (en) * | 1988-04-29 | 1989-02-14 | E. R. Squibb & Sons, Inc. | Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors |
EP0344383A1 (en) * | 1988-06-02 | 1989-12-06 | Merrell Dow Pharmaceuticals Inc. | Novel alpha-Glucosidase inhibitors |
JP2681162B2 (ja) | 1988-07-04 | 1997-11-26 | コニカ株式会社 | ハロゲン化銀カラー写真感光材料 |
DE3836675A1 (de) * | 1988-10-28 | 1990-05-03 | Hoechst Ag | Glykosidase-inhibitor salbostatin, verfahren zu seiner herstellung und seine verwendung |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5504078A (en) * | 1990-06-08 | 1996-04-02 | Merrell Dow Pharmaceuticals Inc. | α-glucosidase inhibitors |
EP0618803A4 (en) * | 1991-12-19 | 1995-03-22 | Southwest Found Biomed Res | POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS. |
JPH07503737A (ja) * | 1992-05-28 | 1995-04-20 | フアイザー・インコーポレイテツド | アシル補酵素a:コレステロールアシルトランスフェラーゼ(acat)の阻害剤としての新規なn−アリールおよびn−ヘテロアリール尿素誘導体 |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5284971A (en) * | 1992-07-16 | 1994-02-08 | Syntex (U.S.A.) Inc. | 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents |
DK0580550T3 (da) * | 1992-07-21 | 1998-02-02 | Ciba Geigy Ag | Oxamidsyrederivater som hypercholesterolæmiske midler |
JP2789134B2 (ja) * | 1992-09-28 | 1998-08-20 | ファイザー・インク. | 糖尿病の合併症を制御する置換ピリミジン類 |
JPH06332264A (ja) | 1993-05-24 | 1994-12-02 | Hodogaya Chem Co Ltd | 静電荷像現像用トナー |
US5596106A (en) * | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
DE4435477A1 (de) * | 1994-10-04 | 1996-04-11 | Bayer Ag | Cycloalkano-indol- und -azaindol-derivate |
US5521186A (en) * | 1994-10-27 | 1996-05-28 | Janssen Pharmaceutica N.V. | Apolipoprotein-β synthesis inhibitors |
US5929075A (en) * | 1994-10-27 | 1999-07-27 | Janssen Pharmaceutica, N.V. | Apolipoprotein-B synthesis inhibitors |
WO1996039384A1 (en) * | 1995-06-06 | 1996-12-12 | Pfizer, Inc. | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
MX9709914A (es) * | 1995-06-07 | 1998-03-31 | Pfizer | Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos. |
JP3656680B2 (ja) | 1995-09-21 | 2005-06-08 | 株式会社リコー | 可逆性感熱発色組成物、およびそれを用いた可逆性記録媒体 |
YU23499A (sh) * | 1996-11-27 | 2001-07-10 | Pfizer Inc. | Inhibitorski amidi apo-b-sekrecije/mtp-a |
US6794511B2 (en) * | 1997-03-04 | 2004-09-21 | G. D. Searle | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
US6696449B2 (en) * | 1997-03-04 | 2004-02-24 | Pharmacia Corporation | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
KR20000075954A (ko) * | 1997-03-04 | 2000-12-26 | 죤 에이치. 뷰센 | N-히드록시 4-술포닐 부탄아미드 화합물 |
US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
ES2244082T3 (es) | 1997-07-11 | 2005-12-01 | Smithkline Beecham Plc | Derivados de sulfonamida que son antagonistas del receptor 5-ht6 y procedimiento para su preparacion. |
KR20010033470A (ko) | 1997-12-23 | 2001-04-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 염증성 질병과 아테롬성경화증의 치료 또는 예방을 위한티오우레아 및 벤즈아미드 화합물, 조성물 및 방법 |
CA2318731C (en) | 1998-01-29 | 2012-05-29 | Tularik Inc. | Ppar-gamma modulators |
US6583157B2 (en) | 1998-01-29 | 2003-06-24 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
ATE369848T1 (de) * | 1998-04-14 | 2007-09-15 | Gen Hospital Corp | Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie |
KR100720844B1 (ko) * | 1998-07-08 | 2007-05-25 | 사노피-아벤티스 도이칠란트 게엠베하 | 황 치환된 설포닐아미노카복실산 n-아릴아미드, 이의 제조방법, 및 이를 함유하는 약제학적 제제 |
KR100652994B1 (ko) * | 1998-09-11 | 2006-11-30 | 아방티 파르마 소시에테 아노님 | 아제티딘 유도체, 이의 제조방법 및 이를 함유하는 약제 |
GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
JP2001089412A (ja) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | ベンゼン誘導体またはその医薬的に許容される塩 |
GB0007934D0 (en) | 2000-03-31 | 2000-05-17 | Darwin Discovery Ltd | Chemical compounds |
US6653332B2 (en) | 2000-05-03 | 2003-11-25 | Tularik Inc. | Combination therapeutic compositions and method of use |
UA82048C2 (uk) | 2000-11-10 | 2008-03-11 | Эли Лилли Энд Компани | Агоністи альфа-рецепторів, активованих проліфератором пероксисом |
ATE352551T1 (de) * | 2001-03-30 | 2007-02-15 | Pfizer Prod Inc | Pyridazinon aldose reductase inhibitoren |
KR20040012905A (ko) | 2001-06-07 | 2004-02-11 | 일라이 릴리 앤드 캄파니 | 페록시좀 증식제 활성화 수용체의 조절제 |
US6540436B2 (en) * | 2001-07-23 | 2003-04-01 | Rain Bird Corporation | Deep root watering unit |
TW550839B (en) | 2001-07-25 | 2003-09-01 | Shinetsu Handotai Kk | Light emitting element and method for manufacturing thereof |
GB2378179A (en) * | 2001-08-03 | 2003-02-05 | Pantherix Ltd | Aromatic sulfonamides and their use in treating bacterial diseases |
US7371777B2 (en) | 2001-08-17 | 2008-05-13 | Eisai Co., Ltd. | Cyclic compound and PPAR agonist |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
WO2003043997A1 (en) | 2001-11-15 | 2003-05-30 | Eli Lilly And Company | Peroxisome proliferator activated receptor alpha agonists |
JP2003292439A (ja) * | 2002-02-04 | 2003-10-15 | Sumitomo Pharmaceut Co Ltd | 新規ピロール誘導体からなるppar活性化剤 |
AU2003207808A1 (en) * | 2002-02-21 | 2003-09-09 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
AU2003219934A1 (en) * | 2002-03-06 | 2003-09-22 | Merck And Co., Inc. | Method of treatment or prevention of obesity |
WO2003087044A2 (en) | 2002-04-09 | 2003-10-23 | 7Tm Pharma A/S | Novel carboxamide compounds for use in mch receptor related disorders |
NZ537685A (en) * | 2002-07-29 | 2007-06-29 | Hoffmann La Roche | Novel benzodioxoles |
AU2003262947A1 (en) * | 2002-08-30 | 2004-03-19 | Pharmacia And Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
US7329658B2 (en) * | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US20040204450A1 (en) * | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
US7141669B2 (en) * | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US20050022815A1 (en) * | 2003-06-25 | 2005-02-03 | Sunrise Medical Hhg Inc. | Apparatus and method for monitoring supplemental oxygen usage |
WO2005014534A1 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
EA010369B1 (ru) * | 2004-02-04 | 2008-08-29 | Пфайзер Продактс Инк. | Замещенные хинолиновые соединения |
CA2558585C (en) * | 2004-02-27 | 2010-10-12 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
EP1722789A2 (en) * | 2004-03-08 | 2006-11-22 | Amgen Inc. | Therapeutic modulation of ppar (gamma) activity |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
WO2005103022A1 (en) * | 2004-04-20 | 2005-11-03 | Transtech Pharma, Inc. | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
US6967808B1 (en) * | 2004-05-13 | 2005-11-22 | Hitachi Global Storage Technologies Netherlands B.V. | Data recording system with servo pattern having pseudo-random binary sequences |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
-
2004
- 2004-12-16 US US11/012,139 patent/US7262318B2/en not_active Expired - Fee Related
-
2005
- 2005-02-23 DO DO2005P000025A patent/DOP2005000025A/es unknown
- 2005-02-28 AU AU2005225628A patent/AU2005225628B2/en not_active Expired - Fee Related
- 2005-02-28 WO PCT/IB2005/000526 patent/WO2005092845A1/en active Application Filing
- 2005-02-28 BR BRPI0508555-1A patent/BRPI0508555A/pt not_active IP Right Cessation
- 2005-02-28 EA EA200601442A patent/EA200601442A1/ru unknown
- 2005-02-28 AP AP2006003714A patent/AP2006003714A0/xx unknown
- 2005-02-28 EP EP05708637A patent/EP1725524A1/en not_active Withdrawn
- 2005-02-28 CA CA002559035A patent/CA2559035A1/en not_active Abandoned
- 2005-02-28 JP JP2007502428A patent/JP2007528387A/ja not_active Withdrawn
- 2005-02-28 KR KR1020067018485A patent/KR20070001173A/ko active IP Right Grant
- 2005-03-08 PE PE2005000265A patent/PE20051147A1/es not_active Application Discontinuation
- 2005-03-08 AR ARP050100890A patent/AR048260A1/es not_active Application Discontinuation
- 2005-03-09 PA PA20058625701A patent/PA8625701A1/es unknown
- 2005-03-09 TW TW094107153A patent/TW200610525A/zh unknown
- 2005-03-09 DO DO2005000034A patent/DOP2005000034A/es unknown
- 2005-03-10 UY UY28794A patent/UY28794A1/es not_active Application Discontinuation
- 2005-03-10 SV SV2005002047A patent/SV2005002047A/es not_active Application Discontinuation
- 2005-03-10 NL NL1028519A patent/NL1028519C2/nl not_active IP Right Cessation
-
2006
- 2006-06-16 US US11/424,626 patent/US20060258723A1/en not_active Abandoned
- 2006-08-22 IL IL177631A patent/IL177631A0/en unknown
- 2006-09-08 MA MA29311A patent/MA28461B1/fr unknown
- 2006-09-08 EC EC2006006834A patent/ECSP066834A/es unknown
- 2006-10-10 NO NO20064615A patent/NO20064615L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20070001173A (ko) | 2007-01-03 |
MA28461B1 (fr) | 2007-03-01 |
TW200610525A (en) | 2006-04-01 |
US7262318B2 (en) | 2007-08-28 |
NL1028519A1 (nl) | 2005-09-13 |
AP2006003714A0 (en) | 2006-08-31 |
DOP2005000034A (es) | 2005-12-15 |
NL1028519C2 (nl) | 2006-06-22 |
CA2559035A1 (en) | 2005-10-06 |
US20060258723A1 (en) | 2006-11-16 |
BRPI0508555A (pt) | 2007-08-07 |
JP2007528387A (ja) | 2007-10-11 |
EA200601442A1 (ru) | 2007-02-27 |
ECSP066834A (es) | 2006-12-29 |
IL177631A0 (en) | 2006-12-31 |
PE20051147A1 (es) | 2006-01-28 |
US20050228015A1 (en) | 2005-10-13 |
EP1725524A1 (en) | 2006-11-29 |
DOP2005000025A (es) | 2006-11-15 |
AU2005225628A1 (en) | 2005-10-06 |
AU2005225628B2 (en) | 2008-09-11 |
UY28794A1 (es) | 2005-10-31 |
AR048260A1 (es) | 2006-04-12 |
PA8625701A1 (es) | 2006-01-25 |
SV2005002047A (es) | 2005-12-13 |
WO2005092845A1 (en) | 2005-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20064615L (no) | Substituerte heteroaryl- og fenylsulfamoylforbindelser | |
NO20070511L (no) | Substituerte heteroaryl- og fenylsulfamoylforbindelser | |
NO20073025L (no) | Dibenzylaminforbindelser og derivater | |
EA200500629A1 (ru) | Активаторы рецепторов, активируемых пролифератором пероксисом (ppar) | |
AP2002002426A0 (en) | Ppar agonists | |
RS20050395A (en) | Ppar activators | |
NO20083642L (no) | Dibenzylaminderivater som CETP-inhibitorer | |
NO20071510L (no) | 4-Amino-substituerte-2-substituerte-1,2,3,4-tetrahydrokinolinforbindelser | |
EA201101084A1 (ru) | Феноксиуксусные кислоты в качестве активаторов ppar дельта | |
EA200970088A1 (ru) | Модуляторы метаболизма и лечение связанных с ним нарушений | |
NO20073140L (no) | Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser | |
NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
NO20051100L (no) | Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer | |
NO20070139L (no) | Heterosykliske derivater for behandling av hyperlipidemi og relaterte sykdommer | |
NO20075731L (no) | Inhibitorer av mikrosomalt triglyceridtransferprotein og APO-B-sekresjon | |
NO20083501L (no) | Azaindoler som er anvendelige som inhibitorer for Janus-kinaser | |
DK2358717T3 (da) | Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes | |
ECSP056040A (es) | 1,2, 4 SUSTITUIDO 1,2,3,4-TETRAHIDRO Y 1,2, DIHIDRO-QUINOLINA y 1,2,3,4-TETRADHIDRO-QUINOXALINA-DERIVADOS COMO INHIBIDORES CETP PARA EL TRATAMIENTO DE ATEROSCLEROSIS Y OBESIDAD | |
NO20090692L (no) | Farmasoytiske og kostholdsprodukter som omfatter vitamin K2 | |
EA200801815A1 (ru) | Дибензиламиносоединения и производные | |
TW200616964A (en) | Quinoline compounds | |
EA200971020A1 (ru) | Лечение сердечно-сосудистого заболевания и дислипидемии с использованием ингибиторов секреторной фосфолипазы а(spla) и способы комбинированного лечения с ингибитором spla | |
NO20070141L (no) | Sma molekyler for behandling av hyperkolesterolemi og relaterte sykdommer | |
CR8567A (es) | Compuestos de heteroaril-y fenilsulfamoilo sustituidos | |
NO20070140L (no) | Mediatorer av revers kolesteroltransport for behandling av hyperkolesterolemi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |